Vycor Medical Reports 17% Revenue Growth, Achieves Operating Profit in 2025

summarizeSummary

Vycor Medical announced its financial results for the year ended December 31, 2025, reporting a 17% increase in revenue and a return to GAAP operating profit.

check_boxKey Events

• Strong Revenue Growth

  Total revenue increased by 17% to $1,863,400 for the year ended December 31, 2025, with the Vycor Medical division (VBAS) growing 18%.

• Achieved Operating Profit

  The company reported a GAAP operating profit of $33,900 for 2025, a significant improvement from an operating loss of $(9,145) in 2024.

• Reduced Net Loss

  GAAP net loss available to common stockholders decreased to $(396,796) in 2025 from $(431,570) in 2024.

• Operational Milestones

  The Vycor Medical division saw increased international sales and 7 new peer-reviewed studies for its VBAS system. NovaVision also published a new clinical study validating its NeuroEyeCoach program for home use.

auto_awesomeAnalysis

Vycor Medical reported a significant operational turnaround for the year ended December 31, 2025, achieving a GAAP operating profit of $33,900 compared to an operating loss in the prior year. This positive shift was driven by a 17% increase in total revenue, reaching $1.86 million, primarily from its Vycor Medical division. While the company still reported a net loss, it was reduced from the previous year. These results indicate improved operational efficiency and market penetration for its core products, providing a positive signal amidst the broader financial challenges highlighted in the concurrently filed 10-K, which noted substantial doubt about the company's ability to continue as a going concern.